Since patients with concomitant mutations in DNMT3A, FLT3 and NPM1 (index group) had been reported to possibly represent a distinctive genomic subset of de novo AML with unique characteristics at the mRNA, miRNA, and epigenetic levels [1], their features were first compared to those of patients in other mutation groups. This evidence concerns the gene NPM1 and acute myeloid leukemia.